Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities.

Immunotargets Ther · 2013 · PMC4928369 · PMID 27471690

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

There was a nonsignificant trend towards longer median overall survival in the temsirolimus group compared with the combination temsirolimus/IFN-α and IFN-α groups (10.9 months vs 8.4 months vs 7.3 months, respectively).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.